VISUALIZING CHALLENGES OF GST ON DIFFERENT CORNERS OF PHARMACEUTICAL INDUSTRY
{ DOWNLOAD AS PDF }
ABOUT AUTHORS
ABDUL KHALID QUADRI*, MD. BARKATH ALI SHAMS
Department of Pharmacy practice, Deccan School of Pharmacy, Hyderabad-500001, Telangana, India
*a.k.quadri4all@gmail.com
ABSTRACT
The Indian pharmaceutical industry is amongst the largest producer of pharmaceutical products in the world (by volume). The pharmaceutical sector is witnessing high growth rate over the past 8-10 years, it has been burdened with diminishing margins. The Indian pharmaceutical industry is facing pressures of increasing span control on account of changing regulations. GST which embodies the principle of one nation, one tax, one market is aimed at unifying the country’s INRs 124.9 trillion economy and 1.3 billion people into a common market. For corporates, the elimination of multiple taxes will improve the ease of doing business. And for consumers the biggest advantage would be in terms of reduction in overall tax burden on goods. In other words GST would make doing business in the country tax-neutral, irrespective of the choice of place of doing business, the important roll-out of GST is to provide a method for companies to simplify their operations, and achieve better efficiencies enabling them to serve customers better. It is also expected that supply chain and other operational planning opportunities and efficiencies may be available, depending on a company’s facts. However, in short–term/transitional phase, pharmaceutical industry, are likely to face a number of challenges, including possibly negative financial impacts, the need to assess existing supply chain structures, the need for reconfiguration of IT systems and more. The warehouse cost can be reduced and rationalized the supply cahin, it has a negative effect on ayurvedic products as its rate will increase from the present rate because of increase in tax slab. GST is expected to fetch a good revenue through increase in medical tourism, GST is surely going to benefit the pharmaceutical industries. It will create a level playing field for generic drug makers, boost medical tourism and simplify the tax structure.
Indian Institute of Chemical Technology, Hyderabad is a premier R&D Institute in India. The Institute had its origin as the Central Laboratories for Scientific & Industrial Research (CLSIR), established in 1944 by the then Government of Hyderabad State. After integration of Hyderabad State with the Indian Union, the laboratory expanded with its growing activities. The main building was formally opened by Pandit Jawaharlal Nehru, the then Prime Minister of India on January 2, 1954. In 1956, the Central Laboratories came under the aegis of the Council of Scientific & Industrial Research (CSIR), New Delhi and was renamed Regional Research Laboratory, Hyderabad (RRL-H).
A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.
Merck Limited (formerly E. Merck Limited) was set up in India as the first Merck subsidiary in Asia in 1967. The Company operates both its Pharmaceuticals and Chemicals businesses in the country.
Under the Drug and Cosmetics Act, the regulation of manufacture, sale and distribution of Drugs is primarily the concern of the State authorities while the Central Authorities are responsible for approval of New Drugs, Clinical Trials in the country, laying down the standards for Drugs, control over the quality of imported Drugs, coordination of the activities of State Drug Control Organisations and providing expert advice with a view of bring about the uniformity in the enforcement of the Drugs and Cosmetics Act. Drug Controller General of India is responsible for approval of licenses of specified categories of Drugs such as blood and blood products, I. V. Fluids, Vaccine and Sera. Central Drugs Standard Control Organization Head quarter is located at FDA Bhawan, Kotla Road, New Delhi 110002 and functions under the Directorate General of Health Services.
